Analysts expect that Intra-Cellular Therapies Inc (NASDAQ:ITCI) will announce earnings per share (EPS) of ($0.90) for the current quarter, Zacks reports. Zero analysts have provided estimates for Intra-Cellular Therapies’ earnings, with the highest EPS estimate coming in at ($0.87) and the lowest estimate coming in at ($0.94). Intra-Cellular Therapies reported earnings per share of ($0.65) in the same quarter last year, which would indicate a negative year over year growth rate of 38.5%. The company is expected to announce its next quarterly earnings report on Thursday, May 2nd.
On average, analysts expect that Intra-Cellular Therapies will report full-year earnings of ($4.06) per share for the current financial year, with EPS estimates ranging from ($4.15) to ($4.03). For the next fiscal year, analysts forecast that the firm will report earnings of ($3.09) per share, with EPS estimates ranging from ($3.90) to ($2.54). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Intra-Cellular Therapies.
Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.16.
Shares of ITCI traded up $0.02 during mid-day trading on Friday, hitting $13.49. The company’s stock had a trading volume of 17,757 shares, compared to its average volume of 322,109. The stock has a market capitalization of $712.66 million, a PE ratio of -4.75 and a beta of 1.38. Intra-Cellular Therapies has a 52-week low of $10.21 and a 52-week high of $23.64.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Samlyn Capital LLC boosted its position in shares of Intra-Cellular Therapies by 64.2% in the 4th quarter. Samlyn Capital LLC now owns 1,266,138 shares of the biopharmaceutical company’s stock valued at $14,421,000 after purchasing an additional 494,918 shares during the period. Norges Bank acquired a new position in Intra-Cellular Therapies during the 4th quarter valued at about $3,759,000. General American Investors Co. Inc. acquired a new position in Intra-Cellular Therapies during the 4th quarter valued at about $3,416,000. Rhenman & Partners Asset Management AB boosted its stake in Intra-Cellular Therapies by 43.9% during the 1st quarter. Rhenman & Partners Asset Management AB now owns 949,833 shares of the biopharmaceutical company’s stock valued at $11,569,000 after purchasing an additional 289,851 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in Intra-Cellular Therapies during the 4th quarter valued at about $2,194,000. Hedge funds and other institutional investors own 69.40% of the company’s stock.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
Read More: How liquidity affects the bid-ask spread
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.